Reducing Suicide Risk Associated With Weight Loss
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years old
- At least 5 pounds weight suppression
- Engaged in non-suicidal self-injury at least once in past month
Exclusion Criteria:
- Indicated being "sure" of suicide attempt on eligibility screener
- Live outside of the United States
- Currently pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Body Acceptance Program
The Body Acceptance Program (BAP) is the active condition.
Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
|
The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
Other Names:
|
|
No Intervention: Waitlist control
Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline on the Self-Injurious Thoughts and Behaviors Interview-Short Form (self-report) at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Self-harm frequency and likelihood
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline on the "Body Esteem Scale: Appearance" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's appearance; scores are summed and range from 0-40, higher scores indicate greater appearance esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the "Body Esteem Scale: Weight" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's weight; scores are summed and range from 0-32, higher scores indicate greater weight esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the "Body Esteem Scale: Attribution" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's characteristics; scores are summed and range from 0-20, higher scores indicate greater self-esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Beck Depression Inventory II at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Depressive symptoms
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Body Shape Questionnaire (8-item version #3) at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Assessment of weight and shape concerns
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Positive and Negative Affect Schedule at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Captures current positive and negative affect
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pamela Keel, Ph.D., Florida State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10274002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.